Stockscreener 앱 받기
762.00
0.69%
5.19
시간 외 거래:
762.00
Regeneron Pharmaceuticals Inc 주식(REGN)의 최신 뉴스
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria - Nasdaq
Regeneron Says Samsung Eye Med Biosimilar Will Infringe IP - Law360
Peering Into Regeneron Pharmaceuticals's Recent Short Interest - Benzinga
Braun Stacey Associates Inc. Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Cutaneous Squamous Cell Carcinoma Market Geographical - openPR
2 Top Growth Stocks to Buy on the Dip - AOL
Swiss National Bank Acquires 2,000 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Seizert Capital Partners LLC Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis - GlobeNewswire Inc.
Mizuho Securities USA LLC Acquires 51,162 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by CIBC Asset Management Inc - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Wolfe Research - MarketBeat
Citigroup Initiates Coverage of Regeneron Pharmaceuticals (REGN) with Neutral Recommendation - MSN
Regeneron to “vigorously defend” against DOJ on Eylea pricing complaint - MSN
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria - Pharmaceutical Technology
Simplify Asset Management Inc. Purchases 3,231 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Check Out What Whales Are Doing With REGN - Benzinga
Regeneron Pharmaceuticals (NASDAQ:REGN) Coverage Initiated at Wolfe Research - MarketBeat
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease - Benzinga
Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S. - Seeking Alpha
ING Groep NV Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
FDA to review Sanofi, Regeneron’s Dupixent sBLA for CSU - Pharmaceutical Business Review
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Citigroup - MarketBeat
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU - MarketWatch
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria - GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous - The Bakersfield Californian
Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Regeneron stock touches 52-week low at $785.31 By Investing.com - Investing.com Nigeria
Regeneron stock touches 52-week low at $785.31 - Investing.com
Citigroup Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) - MarketBeat
28 Analysts Have This To Say About Regeneron Pharmaceuticals - Benzinga
Victory Capital Management Inc. Sells 2,273 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Los Angeles Capital Management LLC Sells 773 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Citi initiated coverage on Regeneron Pharmaceuticals setting a price target of $895 - Investing.com
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals' SWOT analysis: stock faces biosimilar challenge, pipeline promise - Investing.com
Parametrica Management Ltd Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease - Yahoo Finance
MQS Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Dillon & Associates Inc. Buys 878 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH - The Manila Times
Aigen Investment Management LP Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron to Unveil Breakthrough Blood Cancer Data: 23 Studies at ASH 2024 | REGN Stock News - StockTitan
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by OVERSEA CHINESE BANKING Corp Ltd - MarketBeat
Sanofi/Regeneron Pharmaceuticals' DUPIXENT Approval Marks a Significant Shift in Chronic Obstructive Pulmonary Disease Treatment Landscape | DelveInsight - PR Newswire
Bronte Capital Management Pty Ltd. Has $144.06 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $316.96 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Baker Avenue Asset Management LP Invests $707,000 in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Familial Lipoprotein Lipase Deficiency Market Research - openPR
Regeneron Announces Investor Conference Presentations - The Manila Times
Regeneron (REGN) to Present at Two Major Healthcare Investor Conferences | REGN Stock News - StockTitan
Analyst recommendations: Moderna, Bristol-Myers Squibb Company, Regeneron Pharmaceuticals, Arista Networks... - Marketscreener.com
1,269 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Acquired by Catalytic Wealth RIA LLC - MarketBeat
We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease - Yahoo Finance
(REGN) Proactive Strategies - Stock Traders Daily
Assetmark Inc. Has $109.31 Million Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Eylea headwinds said to be behind Regeneron’s post-Q3 plunge - MSN
Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Summit Global Investments Buys 2,195 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by AIA Group Ltd - MarketBeat
ARK Investment Management LLC Has $15.93 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Principal Financial Group Inc. Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) - MarketBeat
Rep. Josh Gottheimer Sells Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Mcdonald Capital Investors Inc. CA - MarketBeat
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by General American Investors Co. Inc. - MarketBeat
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients - Pharmaceutical Technology
0.28%
1.40%
자본화:
|
볼륨(24시간):